Novavax is a biotechnology company based in Gaithersburg, Maryland, focused on developing recombinant vaccines, including its COVID-19 vaccines Nuvaxovid and other candidates. The company employs 1,543 people and utilizes advanced nanoparticle technology and its Matrix-M adjuvant to enhance immune responses.
NVAX filed a patent for "sars-cov-2 vaccine compositions" on Wed, April 24, 2024. The patent was officially published on Thu, November 14, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
